Mailed FIT-DNA Increases Colorectal Cancer Screening Rates in Community Health Centers

Colorectal cancer remains the second leading cause of cancer-related mortality in the United States, despite the proven efficacy of early detection in reducing both incidence and death [1, 2, 3]. Meta-analysis data indicate that screening with colonoscopy or sigmoidoscopy can reduce colorectal cancer incidence by 20 percent (RR: 0.80, 95% CI: 0.77 to 0.83) and cancer-specific mortality by 26 percent (RR: 0.74, 95% CI: 0.69 to 0.80) [4]. While visual examinations are primary tools for prevention through the removal of precancerous lesions, stool-based modalities like the fecal immunochemical test (a diagnostic assay that uses antibodies to detect human hemoglobin in stool) offer a less invasive alternative with a pooled sensitivity of 75 percent and specificity of 89 percent for cancer detection [5, 6]. Current guidelines emphasize that any screening is better than none [7], yet adherence remains suboptimal in underresourced settings where patients face significant socioeconomic barriers [8]. Patient navigation (a strategy using trained personnel to identify and overcome individual barriers to care) has emerged as a vital tool to improve participation and reduce the time from a positive screen to diagnostic follow-up [9]. A new study evaluates how different mailed outreach protocols and stool-based testing technologies influence screening uptake within community health centers, providing actionable data for clinicians managing high-risk populations.